Biotech slump is buying opportunity

Biotechnology stocks are in a bear market. The Nasdaq Biotech index (NBI) has plunged by more than 20% since its record high in February.

In April, of the index’s 121 stocks, only half a dozen or so “have managed to hold their heads above water”, say Rodrigo Campos and Caroline Valetkevitch on Reuters.com. It’s part of a wider trend.

“Investors are dumping what did well last year, and buying the stuff that did badly,” notes the FT’s James Mackintosh. ‘Old’ technology stocks, classic pharmaceuticals and emerging market shares are starting to come back into fashion in what “looks very much like a bout of profit-taking”.

This does not mean biotech is doomed. The slump in stock prices actually helps the industry over the long term, says Steven Syre in The Boston Globe.

“A biotech stock collapse from even greater heights could have shut off public funding to promising new companies and for a long time limited the ability of established biotechs to grow.”

The price/earnings growth (PEG) ratio suggests that biotech shares are even starting to look decent value. Generally, stocks with a PEG of below one are seen as being cheap.

More than 20 Nasdaq biotech components, including Biogen Idec (BIIB) and Gilead Sciences (GILD), now trade on PEG ratios of below one.

If you’re interested in buying into the sector, The International Biotech Trust (LSE: IBT), which counts Biogen and Gilead as its top stock picks, trades on a 20% discount to its net asset value. The Biotech Growth Trust (LSE: BIOG) is on a discount of 6.7%.

66% off newsstand price

12 issues (and much more) for just £12

That’s right. We’ll give you 12 issues of MoneyWeek magazine, complete access to our exclusive web articles, our latest wealth building reports and videos as well as our subscriber-only email… for just £12.

That’s just £1 per week for Britain’s best-selling financial magazine.

Click here to take advantage of our offer

Britain is leaving the European Union. Donald Trump is reducing America’s role in global markets. Both will have profound consequences for you as an investor.

MoneyWeek analyses the critical issues facing British investors on a weekly basis. And, unlike other publications, we provide you with the solutions to help you turn a situation to your financial advantage.

Take up our offer today, and we’ll send you three of our most important investment reports:

All three of these reports are yours when you take up our 12 issues for £12 offer today.

MoneyWeek has been advising private British investors on what to do with their money since 2000. Our calls over that period have enabled our readers to both make and save a great deal of money – hence our position as the UK’s most-trusted investment publication.

Click here to subscribe for just £12